Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

Published:December 19, 2022DOI:



      In this study, we report real-world results from the 5-year follow-up data of urothelial carcinoma patients treated with immune checkpoint blockade therapies (ICTs).

      Patients and Methods

      Metastatic urothelial carcinoma patients treated with at least one course of ICT were included in the study. The primary endpoint was overall response rate (ORR), and secondary endpoints were overall survival (OS), progression-free survival (PFS), duration of treatment with ICT, and safety. Median follow-up, PFS, and OS were estimated by using the Kaplan-Meier method.


      Data of 201 eligible patients were analyzed. The median age of the patients was 66 (37-86) years, and 156 (84.3%) were male. The majority of patients (94.6%) had Eastern Cooperative Oncology Group (ECOG) PS scores of 0 to 1 and primary tumor in the bladder was predominant (87.5%). The median follow-up time was 54 (1.15-65) months. The rate of complete response (CR) to ICT, partial response (PR) rate, and ORR were 10.4% (n = 21), 22.4% (n = 45), and 32.4% (n = 66), respectively. The median duration of response (DOR) was 34.8 months (95% confidence interval [CI], 29.2-42.1). Of the 66 patients who responded to treatment, 28 (42%) had an ongoing response at the time of the analysis. Median PFS and OS were 3.8 (2.6-5.8) months and 9.4 (7.4-11.4) months, respectively. The 5-year PFS and OS rates were 9.8% and 12.8%, respectively. Fifty-eight percent of patients experienced a treatment-related adverse event of any grade, and 33 (16.4%) patients had a grade 3 to 4 adverse event.


      This 5-year analysis of real-world data confirms the durable response and long-term survival with ICT in metastatic urothelial carcinoma patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ferlay J
        • Soerjomataram I
        • Dikshit R
        • et al.
        Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
        Int J Cancer. 2015; 136: E359-E386
      1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. SEER Cancer Statistics Factsheets: Bladder Cancer. Available at: Accessed: 2022.

        • Von der Maase H
        • Sengelov L
        • Roberts JT
        • et al.
        Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
        J Clin Oncol. 2005; 23: 4602-4608
        • Powles T
        • Park SH
        • Voog E
        • et al.
        Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.
        N Engl J Med. 2020; 383: 1218-1230
        • Vuky J
        • Balar AV
        • Castellano D
        • et al.
        Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.
        J Clin Oncol. 2020; 38: 2658-2666
        • Balar AV
        • Galsky MD
        • Rosenberg JE
        • et al.
        Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
        Lancet. 2017; 389: 67-76
        • Bellmunt J
        • de Wit R
        • Vaugh DJ
        • et al.
        Pembrolizumab as second-line therapy for advanced urothelial carcinoma.
        N Engl J Med. 2017; 376: 1015-1026
        • Sharma P
        • Retz M
        • Siefker-Radtke A
        • et al.
        Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate275): a multicentre, single-arm, phase 2 trial.
        Lancet Oncol. 2017; 18: 312-322
        • Rosenberg JE
        • Hoffman-Censits J
        • Powles T
        • et al.
        Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
        Lancet. 2016; 387: 1909-1920
        • Tural D
        • Olmez O.F
        • Sumbul A.T
        • et al.
        Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience.
        Eur Urol Focus. 2020; 5 (S2405-4569(20)30269-8): 1061-1066
        • Powles T
        • Durán I
        • van der Heijden MS
        • et al.
        Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
        Lancet. 2018; : 748-757
        • Kennedy-Martin T
        • Curtis S
        • Faries D
        • Robinson S
        • Johnston J
        A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results.
        Trials. 2015; : 16
        • Hussain SA
        • Birtle A
        • Crabb S
        • et al.
        From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma.
        Eur Urol Oncol. 2018; 1: 486-500
        • Bellmunt J
        • Albanell J
        • Paz-Ares L
        • et al.
        Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
        Cancer. 2002; 95: 751-757
        • Galsky MD
        • Hahn NM
        • Rosenberg JE
        • et al.
        Defining "cisplatin ineligible" patients with metastatic bladder cancer.
        J Clin Oncol. 2011; 29: 238
      2. Rosenberg JE, Galsky MD, Balar AV, et al. Poster presented at: ESMO 202. Abstract 4262.

      3. SEER. Available at: Accessed: June 25, 2022.

        • De Santis M
        • Bellmunt J
        • Mead G
        • et al.
        Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
        J Clin Oncol. 2012; 30: 191-199
        • Tural D
        • Ölmez ÖF
        • Sümbül AT
        • et al.
        Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
        Int J Clin Oncol. 2021; 26: 1506-1513
        • Tural D
        • Selçukbiricik F
        • Ölmez ÖF
        • et al.
        Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma.
        Int J Clin Oncol. 2022; 27: 585-591